Trial Profile

Phase 1 clinical study of VENT-02

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VENT 02 (Primary)
Indications Alzheimer's disease; Epilepsy; Neurodegenerative disorders; Parkinson's disease
Focus Adverse reactions; Pharmacodynamics
Sponsors Ventus Therapeutics

Most Recent Events

17 Apr 2024 Results presented in the Ventus Therapeutics Media Release.
22 Aug 2023 According to a Ventus Therapeutics media release, first participant has been dosed in this trial and preliminary results re expected in the first half of 2024.
22 Aug 2023 Status changed from planning to recruiting, according to a Ventus Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com